Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma

Figures & data

Figure 1 Mad2 expression in PGI-DLBCL. (A) Immunohistochemical staining of Mad2. PGI-DLBCL (stomach) (400×). Mad2 was stained in the cytoplasm and nucleus of tumor cells. (B) Positive control for Mad2 expression. Normal tonsil (200×). Mad2 was mainly expressed in the germinal center. (C) Negative control for Mad2 staining. PGI-DLBCL (stomach) (400×). (D) Statistic analysis of Mad2 expression in PGI-DLBCL. A PGI-DLBCL. B Reactive lymph node (germinal center). C Reactive lymph node (non-germinal center). D Normal gastrointestinal tissue (lymphoid nodule). E Nodal lymphoma of DLBCL. (※) B–D P < 0.01, (#) E P > 0.05.

Figure 2 Ki-67 expression in PGI-DLBCL (ileum) (400×). Ki-67 was localized to the nucleus of PGI-DLBCL cells.

Figure 3 BCL-6 gene rearrangement in PGI-DLBCL cells (ileocecal) (400×). In normal cell hybridized with the BCL-6 probe, the expected signal pattern is two red and green fusion signals (2F). Nucleus with a translocation breakpoint involving the BCL-6 gene showing a one red, one green, and one fusion (1R1G1F) pattern.

Figure 4 Disease-free survival of patients with PGI-DLBCL. Upper line: low Mad2 expression; lower line: high Mad2 expression.

Table 1 Clinical characteristics of 38 patients with PGI-DLBCL

		Mad2 expression
Variables	Total	High	Low
Number	38	24	14
Gender (M/F)	23/15	16/8	7/7
Age (years)	56.2 (28–88)	55.8 (37–79)	57.1 (28–88)
Stage
I–II	32	19	13
III–IV	6	4	2
B-symptoms	10/38	7/24	3/14
IPI score
0–2	35	22	13
3–5	3	2	1
ECOG-PS
0–1	31	21	10
2–4	7	4	3
Primary location
Gastric	16	10	6
Non-gastric	22	14	8
Gross morphology
Ulcer	13	8	5
Mass	25	16	9
CR (%)	57.9 (22/38)	58.3 (14/24)	57.1 (8/14)
Death	6	4	2

M, male; F, female; IPI, international prognosis index; ECOG-PS, eastern cooperative oncology group-performance status; CR, complete remission.